Parabilis Medicines — Third Quarter 2026 Earnings Summary

Parabilis Medicines reported third-quarter 2026 financial results showing $1.1 billion in cash and cash equivalents, sufficient to fund operations into 2030. The company presented updated Phase 1/2 data for zolucatetide in desmoid tumors at the ESMO Congress 2026, demonstrating a 72.2% objective response rate and a favorable safety profile. Parabilis reached alignment with the U.S. FDA on the design for the upcoming PEDESTAL Phase 3 registrational trial, which is scheduled to begin in the first half of 2027. Additionally, the company initiated a dose-ranging study for zolucatetide in familial adenomatous polyposis and entered a clinical collaboration with Revolution Medicines to evaluate the drug in combination therapies for metastatic colorectal cancer.